1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ganga Pharmaceuticals Ltd.

Ganga Pharmaceuticals Ltd.

BBSE:GANGAPHARM
12.50
INR
+0.50
(+4.17%)
70.94MMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
6.63
6.47
7.41
7.52
8.28
7.58
5.85
6.13
6.37
5.66
5.45
4.78
- -
Basic EPS, GAAP
0.08
0.12
0.18
0.23
0.46
0.46
0.05
0.09
0.1
0.1
0.16
0.17
- -
Free Cash Flow per Basic Share
- -
-2.62
0.01
-0.06
0.2
-0.78
-0.47
-0.55
-0.13
-2.66
-1.4
-2.28
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.49
11.82
12
12.24
12.69
13.18
13.23
13.32
13.42
14.58
14.75
14.06
14.06
Tangible Book Value per Share
6.49
11.82
12
12.24
12.69
13.18
13.23
13.32
13.42
14.58
14.75
14.06
14.06
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
5
5
6
6
Sales/Revenue/Turnover
27
26
30
31
34
31
24
25
26
27
26
28
- -
Operating Margin (%)
14.09
9.9
8.84
10.85
20.03
14.67
-0.87
-0.51
-1.99
0.31
-6.17
-0.54
- -
Depreciation Expense
- -
- -
- -
1
1
1
1
1
1
- -
- -
1
- -
Net Income, GAAP
- -
- -
1
1
2
2
- -
- -
- -
- -
1
1
- -
Effective Tax Rate (%)
31.58
30.59
29.87
25.75
27.61
26
45.58
26
26.01
26.33
16.58
21.5
- -
Profit Margin (%)
1.24
1.85
2.46
3.08
5.56
6.13
0.86
1.52
1.52
1.7
3
3.59
- -
Working Capital
11
34
26
22
24
28
30
32
33
46
53
63
63
LT Debt
15
13
11
9
7
6
7
9
6
4
2
1
1
Total Equity
26
48
49
50
52
54
54
54
55
71
71
83
83
Return on Invested Capital (%)
- -
3.07
2.67
2.94
5.29
3.51
-0.16
-0.13
-0.52
0.08
-1.59
-0.13
- -
Return on Capital (%)
- -
4.42
4.14
4.24
5.16
5.06
1.69
2.48
2.43
2.29
2.59
2.21
- -
Return on Common Equity (%)
- -
1.31
1.53
1.91
3.7
3.59
0.38
0.7
0.72
0.75
1.11
1.31
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
12
13
10
LT Borrowings
2
3
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
6
6
Market Capitalization
49
86
71

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
69
75
76
Cash, Cash Equivalents & STI
3
- -
1
Accounts Receivable, Net
9
10
9
Inventories
12
12
12
Total Current Liabilities
16
16
12
Payables & Accruals
- -
- -
- -
ST Debt
12
13
10
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.99%
9.7%
16.56%
Free Cash Flow
65.78%
449.49%
99.38%
Net Income, GAAP
29.63%
41.29%
28.48%
Sales/Revenue/Turnover
1.29%
3.63%
7.22%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
27
2025
- -
- -
26
2026
- -
- -
28

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.1
2025
- -
- -
0.16
2026
- -
- -
0.17

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bharat Brijmohan Sharma
Full Time Employees
19
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Gangatat, Dhanvantri Marg Mumbai India 401305
IPO Date
Feb 22, 2016
Website
ayurvedganga.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ganga Pharmaceuticals Limited manufactures, markets, and distributes a comprehensive range of Ayurvedic medicines and herbal products targeting various health conditions. Its main product offerings include Ayurvedic medicines for acidity, antidandruff, antioxidants, blood purifiers, skin disorders, constipation, cough and cold, diarrhea, dental care, ear care, hair care, indigestion, kidney stone treatment, liver disorders, sleep inducers, and weight management. The company additionally produces iron tonics, female tonics, rejuvenation tonics, treatments for hemorrhoids and piles, joint pain remedies, and a variety of herbal cosmetic products. Founded in 1989 and headquartered in Mumbai, India, the company has expanded its marketing and distribution footprint domestically and internationally with ties in Saudi Arabia, Dubai, Italy, Romania, and Russia. Recent company developments include continued focus on Ayurvedic product manufacturing and distribution amid stable operations, with no major corporate restructuring or acquisitions publicly reported in the last two years. The company remains engaged in maintaining quality and expanding market reach through strategic marketing alliances and its established product portfolio that supports traditional Ayurvedic health care needs, strengthening its position in the consumer staple and household products segments primarily in India with growing export activities. Its executive management includes Bharat Brijmohan Sharma as Managing Director and it operates in the pharmaceuticals and allied products sector focused on Ayurveda.